Cover Image
市場調查報告書

B細胞成熟抗原 (BCMA) 標靶治療藥的全球市場 (各產品種類 (CAR-T細胞,雙特異性抗體,抗體藥物複合體 (ADC)),不同症狀,各地區):考察,市場規模·佔有率·機會分析,未來預測

B-cell Maturation Antigen (BCMA) Targeted Therapies Market, by Product Type, Indication, and Geography - Insights, Size, Share, Opportunity Analysis, and Industry Forecast till 2025

出版商 Coherent Market Insights 商品編碼 593001
出版日期 內容資訊 英文 130 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
B細胞成熟抗原 (BCMA) 標靶治療藥的全球市場 (各產品種類 (CAR-T細胞,雙特異性抗體,抗體藥物複合體 (ADC)),不同症狀,各地區):考察,市場規模·佔有率·機會分析,未來預測 B-cell Maturation Antigen (BCMA) Targeted Therapies Market, by Product Type, Indication, and Geography - Insights, Size, Share, Opportunity Analysis, and Industry Forecast till 2025
出版日期: 2017年10月20日 內容資訊: 英文 130 Pages
簡介

本報告提供全球B細胞成熟抗原 (BCMA) 標靶治療藥的市場相關分析,提供疾病概要和主要的治療方法,市場基本結構及促進·阻礙因素,整體市場規模預測,各產品種類·不同症狀·各地區的詳細趨勢,主要企業的簡介,產業相關人員今後應致力處理的課題等調查。

第1章 分析對象與前提條件

第2章 市場概要

  • 分析概要
  • 市場現狀

第3章 市場動態,市場機會,開發平台分析

  • 市場動態
    • 推動市場要素
    • 阻礙市場要素
    • 市場機會
  • 開發平台分析
  • 迄今的標靶治療開發趨勢
  • 流行病學

第4章 全球BCMA (B細胞成熟抗原) 標靶治療藥的市場:各產品種類

  • 簡介
  • 抗體藥物複合體 (ADC)
  • CAR-T細胞
  • 雙特異性抗體

第5章 全球BCMA標靶治療藥的市場:不同症狀

  • 簡介
  • 急性淋巴芽球
  • 多發性骨髓瘤

第6章 全球BCMA標靶治療藥的市場:各地區

  • 簡介
    • 潛在的市場規模
  • 北美市場
  • 南美市場
  • 歐洲市場
  • 亞太地區市場
  • 中東市場
  • 非洲市場

第7章 企業簡介

  • Celgene Corporation
    • 企業概要
    • 產品系列
    • 財務實際成果
    • 近幾年主要的動向
    • 策略
  • GlaxoSmithKline plc.
  • Novartis AG
  • Juno Therapeutics
  • Gilead Sciences. Inc
  • Amgen Inc
  • Affimed N.V
  • Poseida Therapeutics, Inc.
  • Autolus Ltd
  • 分析師的見解

第8章 附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄

Recurrence of multiple myeloma has been a highly prevalent health condition, which requires novel and effective immunotherapeutic treatment. According to Leukemia Research by Elsevier, as of 2014, the incidence of multiple myeloma is estimated to be around 120,000 cases per year, with a global prevalence of over one million cases. B-cell maturation antigen (BCMA), is a cell surface protein that is expressed on the malignant plasma cells. This cell surface protein has emerged as a very selective antigen targeted therapy for the treatment of multiple myeloma. BCMA targeted therapies actively involve three major types of immunotherapies on the basis of product class namely, chimeric antigen receptor T-cells (CAR T Cells), bispecific antibodies, and antibody drug conjugates (ADCs). These advanced therapies are expected to improve the survival rate of multiple myeloma patients.

Market Dynamics

Increasing prevalence of multiple myeloma is expected to favor the B-cell maturation antigen (BCMA) targeted therapies market worldwide. According to the American Cancer Society, U.S., in 2016, the lifetime risk for multiple myeloma was around 1 in 143 people, with an estimated 30,280 adults (17,490 men and 12,790 women) diagnosed with multiple myeloma. The mortality rate of the disease was estimated to be 12,590 (6,660 men and 5,930 women) in 2016. Key players are actively involved in the development of immunotherapies targeting BCMA for the treatment of multiple myeloma, the demand for which is expected to increase,  This in turn, is expected to boost development of  novel treatments for relapsed or refractory myeloma. Furthermore, patients undergoing existing drug therapies are prone to the risk of relapse. Hence, B-cell maturation antigen targeted therapy, which primarily addresses this concern is expected to gain rapid traction.

Market Taxonomy

This report segments the global B-cell maturation antigen (BCMA) targeted therapies market on the basis on product type, indication, and regions. On the basis of product type, the market is segmented into antibody drug conjugates, CAR-T cells, bispecific antibodies. On the basis of indication, the market is segmented into acute lymphoblastic leukemia and multiple myeloma. For comprehensive understanding of market dynamics, the global B-cell Maturation Antigen (BCMA) targeted therapies market is analyzed across key geographical regions namely, North America, Europe, Asia Pacific, Latin America, Africa, and Middle East. Each of these regions is analyzed on the basis of market findings across major countries in these regions for a macro-level understanding of the market.

Key Features of the Study:

This report provides in-depth analysis of the global B-cell maturation antigen (BCMA) targeted therapies market and provides pipeline analysis for the same

It elucidates potential opportunity across different segments and explains attractive investment proposition matrix for this market. It provides valuable insights about market drivers, restraints, opportunities, impact analysis, key developments, and competitive landscape

It profiles leading players in the global B-cell maturation antigen (BCMA) targeted therapies market based on the following parameters – company overview, financial performance, product pipeline, geographical presence, and key developments

Key companies covered as a part of this study include Celgene Corporation, GlaxoSmithKline plc, Novartis AG, Juno Therapeutics, Gilead Sciences. Inc., Amgen Inc., Affimed N.V, Poseida Therapeutics, Inc., and Autolus Ltd

Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future BCMA targeted therapies product launch, market expansion, and marketing tactics

The global BCMA targeted therapies market report caters to various stakeholders in this industry including, investors, suppliers, manufacturers, distributors, new entrants, and financial analysts

Stakeholders would have ease in decision-making through the various strategy matrices used in analyzing the B-Cell maturation antigen (BCMA) targeted therapies market

Detailed Segmentation:

  • Global B-cell Maturation Antigen (BCMA) Targeted Therapies Market, By Product Type:
  • Antibody Drug Conjugates
  • CAR-T Cells
  • Bispecific Antibodies
  • Global B-cell Maturation Antigen (BCMA) Targeted Therapies Market, By Indication:
  • Acute Lymphoblastic Leukemia
  • Multiple Myeloma
  • Global B-cell Maturation Antigen (BCMA) Targeted Therapies Market, By Region:
  • North America
  • Overview
  • Epidemiology
  • Latin America
  • Overview
  • Epidemiology
  • Europe
  • Overview
  • Epidemiology
  • Asia Pacific
  • Overview
  • Epidemiology
  • Middle East
  • Overview
  • Epidemiology
  • Africa
  • Overview
  • Epidemiology
  • Company Profiles
  • Celgene Corporation *
  • Company Overview
  • Product Portfolio
  • Financial Performance
  • Key Strategies
  • Recent Developments
  • GlaxoSmithKline plc.
  • Novartis AG
  • Juno Therapeutics
  • Gilead Sciences. Inc
  • Amgen Inc
  • Affimed N.V
  • Poseida Therapeutics, Inc.
  • Autolus Ltd
  •  “*” marked represents similar segmentation in other categories in the respective section.

Table of Contents

1. Research Objective and Assumption

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
  • Market Snapshot

3. Market Dynamics, Opportunity, and Pipeline Analysis

  • Market Dynamics
    • Drivers
    • Restraints
    • Market opportunity
  • Pipeline Analysis
  • Targeted therapies developed till now
  • Epidemiology

4. Global B-cell Maturation Antigen (BCMA) Targeted Therapies Market, By Product Type

  • Introduction
  • Antibody Drug Conjugates
    • Research Details
  • CAR- T cells
    • Research Details
  • Bispecific Antibodies
    • Research Details

5. Global B-cell Maturation Antigen (BCMA) Targeted Therapies Market, By Indication

  • Introduction
  • Acute Lymphoblastic Leukemia
    • Overview
  • Multiple Myeloma
    • Overview

6. Global B-cell Maturation Antigen (BCMA) Targeted Therapies Market, By Regions

  • Introduction
    • Addressable Market
  • North America
    • Overview
    • Epidemiology
  • Latin America
    • Overview
    • Epidemiology
  • Europe
    • Overview
    • Epidemiology
  • Asia Pacific
    • Overview
    • Epidemiology
  • Middle East
    • Overview
    • Epidemiology
  • Africa
    • Overview
    • Epidemiology

7. Company Profiles

  • Celgene Corporation*
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Developments/Updates
    • Strategies
  • GlaxoSmithKline plc.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Developments/Updates
    • Strategies
  • Novartis AG
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Developments/Updates
    • Strategies
  • Juno Therapeutics
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Developments/Updates
    • Strategies
  • Gilead Sciences. Inc
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Developments/Updates
    • Strategies
  • Amgen Inc
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Developments/Updates
    • Strategies
  • Affimed N.V
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Developments/Updates
    • Strategies
  • Poseida Therapeutics, Inc.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Developments/Updates
    • Strategies
  • Autolus Ltd
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Developments/Updates
    • Strategies
  • Analyst Views

8. Section

  • References
  • Research Methodology
  • About Us and Sales Contact
Back to Top